Commercial Assessment Of The Global Industrial Biomanufacturing Market 2027-2037
Industrial biomanufacturing uses living systems - microbes, mammalian, plant and insect cells, and increasingly cell-free enzymatic platforms - to produce molecules that would otherwise be made from petrochemical feedstocks or extracted from natural sources. It spans six commercial domains: biopharmaceuticals, industrial enzymes, biofuels, bioplastics, biochemicals and bio-agritech. The sector's economic case rests on three arguments rather than one. The first is decarbonisation: biological routes displace fossil feedstocks across chemicals, fuels, materials and food ingredients, and where carbon pricing tightens the cost gap narrows structurally rather than cyclically. The second is supply-chain resilience, since fermentation can be sited close to demand and run on local or waste-derived carbon. This has become explicit policy: the United States enacted the BIOSECURE Act in December 2025 and its National Security Commission on Emerging Biotechnology has identified limited domestic scale-up capacity as a structural weakness, while China has published target product lists to direct investment. The third is value capture - biomanufacturing creates new industrial ecosystems in strain design, bioprocess engineering and downstream separation rather than merely substituting inputs.
Biopharmaceuticals remain the largest value pool, with an addressable market approaching $1 trillion by 2030 across monoclonal antibodies, vaccines, recombinant proteins and the faster-growing cell, gene and RNA therapeutic segments. Industrial enzymes represent a mature multi-billion dollar market. Biofuels are the largest volume segment, and bioplastics, biochemicals and bio-agritech expanding from smaller bases. The technology frontier is moving on several fronts simultaneously: AI-driven protein and pathway design compressing design-build-test cycles; continuous and intensified fermentation displacing batch operation; cell-free systems removing the constraints of cell viability; and alternative feedstocks - C1 gases, lignocellulosics and captured CO2 - reducing dependence on food crops.
The sector's record also warrants caution. Between 2019 and 2026 POET halted cellulosic production at Project Liberty, Clariant closed its Podari plant and exited biofuels, Fulcrum BioEnergy and Red Rock Biofuels entered bankruptcy without completing commercial production, both Enerkem sites failed, and Viridos filed for Chapter 11 after ExxonMobil ended a $350 million algae programme. No commercial biomass gasification-Fischer-Tropsch plant operates anywhere. Announced capacity consistently exceeds realised capacity, and forecasts should be read as contingent on a scale-up that has repeatedly proven harder than projected.
The Global Industrial Biomanufacturing Market 2027-2037 provides a comprehensive assessment of industrial biomanufacturing across its six commercial domains, combining technology analysis, market forecasts to 2037 and profiles of more than 1,000 companies. Industrial biomanufacturing has moved from a substitution play to a matter of industrial strategy, driven by decarbonisation targets, supply-chain security concerns and the emergence of AI-enabled biological design. This report examines what is genuinely commercial, what remains pre-commercial, and where announced capacity has failed to materialise. Coverage begins with production platforms - microbial fermentation, mammalian, plant and insect cell culture, transgenic systems and cell-free biomanufacturing - before addressing enabling technologies including synthetic biology, CRISPR-based strain engineering, continuous and intensified processing, downstream separation, and AI and robotics in bioprocess design.
Six market chapters then assess biopharmaceuticals, industrial enzymes, biofuels, bioplastics, biochemicals and bio-agritech. Each covers technology and materials analysis, market drivers, regulations, value chain, technology readiness, addressable market size, risks and opportunities, and global revenue forecasts segmented by product type, application and region. The report includes revenue and volume forecasts to 2037, capacity and consumption series for renewable diesel, biodiesel, bio-jet fuel, bioethanol, biomethane and bio-LNG, and detailed assessments of feedstock availability including waste lipids, lignocellulosics, C1 and C2 gases, and captured CO2. More than 1,080 companies are profiled with descriptions, country of operation and website.
Contents include:
- Executive Summary - definition and scope, processes, key components, economic importance, colours of biotechnology, markets, AI and robotics, emerging technologies Production - microbial fermentation, mammalian cell culture, plant cell culture, insect cell culture, transgenic animals and plants, technologies, scale, mode of operation, host organisms Biopharmaceuticals - overview, technology analysis, market analysis, company profiles Industrial Enzymes (Biocatalysts) - overview, technology analysis, market analysis, company profiles Biofuels - overview, technology analysis, market analysis, company profiles Bioplastics - overview, technology analysis, market analysis, company profiles Biochemicals - overview, technology analysis, market analysis, company profiles Bio-Agritech - overview, technology analysis, market analysis, company profiles
Key Topics Covered
1 EXECUTIVE SUMMARY
1.1 Definition and Scope of Industrial Biomanufacturing
1.2 Overview of Industrial Biomanufacturing Processes
1.3 Key Components of Industrial Biomanufacturing
1.4 Importance of Industrial Biomanufacturing in the Global Economy
1.5 Colours of Biotechnology
1.6 Markets
1.7 AI and Robotics in Biomanufacturing
1.8 Other Advanced and Emerging Technologies in Biomanufacturing
2 PRODUCTION
2.1 Microbial Fermentation
2.2 Mammalian Cell Culture
2.3 Plant Cell Culture
2.4 Insect Cell Culture
2.5 Transgenic Animals
2.6 Transgenic Plants
2.7 Technologies
2.8 Scale of Production
2.9 Mode of Operation
2.10 Host Organisms
2.11 Manufacturing capacity and contract production
2.12 Scale-up economics and the first-of-a-kind problem
2.13 Sustainability accounting and certification
2.14 Water and resource intensity
3 BIOPHARMACEUTICALS
3.1 Overview
3.2 Technology/materials analysis
3.3 Market analysis
3.4 Company profiles
4 INDUSTRIAL ENZYMES (BIOCATALYSTS)
4.1 Overview
4.2 Technology/materials analysis
4.3 Market analysis
4.4 Company profiles
5 BIOFUELS
5.1 Overview
5.2 Technology/materials analysis
5.3 Market analysis
5.4 Company profiles
6 BIOPLASTICS
6.1 Overview
6.2 Technology/materials analysis
6.3 Market analysis
6.4 Company profiles
7 BIOCHEMICALS
7.1 Overview
7.2 Bio-based feedstocks
7.3 Market analysis
7.4 Company profiles
8 BIO-AGRITECH
8.1 Overview
8.2 Technology & materials analysis
8.3 Market analysis
8.4 Company profiles
9 RESEARCH METHODOLOGY
10 REFERENCES
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment